Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06056999
Other study ID # 2023-KY-0277
Secondary ID 2023-NHLHCRF-YYP
Status Recruiting
Phase
First received
Last updated
Start date September 29, 2023
Est. completion date July 2025

Study information

Verified date October 2023
Source China-Japan Friendship Hospital
Contact Guangying Zhu, doctor
Phone +86-010-84205381
Email zryyfa@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational clinical trial is to establish a new method for differentiating benign and malignant pulmonary nodules by peripheral blood detection in patients with pulmonary nodules (<3cm). The main questions it aims to answer is: How to combine blood metabolomic mass spectrometry detection and artificial intelligence image analysis to establish a new model for differentiating benign and malignant pulmonary nodules. Participants will be asked provide 4 mL peripheral blood for the test.


Description:

The aim of this clinical trial is to establish a new method for differentiating benign and malignant pulmonary nodules by the combination of metabolomics analysis and artificial intelligence (AI) analysis. It is expected to improve the accuracy of the identification of benign and malignant pulmonary nodules. Patients with clinical suspected malignant pulmonary nodules will be included in this trial. The subjects will be divided into three group by CT image presentation: (1) pure ground-glass nodule (pGGN), (2) part-solid nodule (PSN), (3) solid nodule (SN). Peripheral blood of subjects will be collected and detected by mass spectrometry to obtain the metabolomic characterization. The classification model of each group will be constructed based on the data analysis algorithm by machine learning. The diagnostic efficacy of the new model combined with the AI image analysis system for differentiating benign and malignant pulmonary nodules will be analyzed.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date July 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years; - CT imaging shows the presence of pulmonary nodule <3cm which is scheduled for puncture biopsy or surgery (i.e., the target lesion), the presence of =2 target lesions of the same type (categorized by density) are allowed; - Subjects are in good condition with Eastern Cooperative Oncology Group (ECOG) scale of 0-2; - Subjects with fair vital organ function, defined as: white blood cells =3.0×10^9/L, platelets =75×10^9/L, hemoglobin =90g/L, alanine aminotransferase and aspartate aminotransferase =2.5 times the upper limit of normal values, and serum creatinine <178µmol/L; - Subjects must have the ability to understand and sign the informed consent in writing voluntarily. Exclusion Criteria: - Imaging examination have suggested the possibility of metastasis at other sites; - =2 target lesions with different type categorized by density; - History of malignant disease; - Severe vascular lesions within the last 3 months, or known significant active infection, during acute/chronic tuberculosis infection, or severe cardiovascular and cerebrovascular diseases, dysfunction of liver and renal, or significant endocrine and metabolic disorders, or other serious concomitant diseases that are not controlled; - The specialist/surgeon assessed that puncture or surgery is not available, with contraindication such as coagulation disorders, cardiorespiratory insufficiency, etc.; - History of uncontrolled epilepsy, central nervous system disease, or psychiatric disorders, that may affect the signing of informed consent; - Pregnant or breastfeeding women; - Other conditions deemed by the investigator to be unsuitable for enrollment.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China China-Japan Friendship Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
China-Japan Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Establish an model for differentiating lung nodules. To establish a new method for differentiating benign and malignant pulmonary nodules by the combination of metabolomics analysis and artificial intelligence (AI) image analysis. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04182893 - Clinical Study of ctDNA and Exosome Combined Detection to Identify Benign and Malignant Pulmonary Nodules
Active, not recruiting NCT03651986 - Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules
Not yet recruiting NCT05067023 - Evaluation for Benign and Malignant Pulmonary Ground-glass Nodules Based on MRI Dynamic Contrast Enhanced Imaging N/A
Completed NCT02146131 - Ultrathin Bronchoscope and Radial Endobronchial Ultrasound (R-EBUS) With Fluoroscopy Versus Standard Fiberoptic Bronchoscopy (FB) (P00029233 ) N/A
Recruiting NCT04462185 - A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers
Recruiting NCT04690790 - Pulmonary Nodule Localization Prospective Validation
Recruiting NCT05525260 - Limonene for Pulmonary Nodule Chemoprevention Phase 2
Completed NCT00629460 - A Pilot Study of PET-CT in the Assessment of Pulmonary Nodules in Children With Malignant Solid Tumors N/A
Completed NCT03420885 - Effects of Ba Duan Jin for Patients With Pulmonary Nodules N/A
Active, not recruiting NCT05091437 - DOuBLED - Doubling Outcomes by Lung Cancer Early Diagnosis